Encoded Therapeutics
Encoded Therapeutics
  • 15
  • 3 434
Dravet Syndrome: Potential Role of Gene Regulation Therapy
Dravet syndrome is a severe, complex, lifelong disorder of the central nervous system, characterized by frequent, prolonged, and difficult-to-treat seizures, significant cognitive delays, sleep abnormalities, motor impairment, and profound behavioral difficulties. There are currently no approved therapies that address the full spectrum of manifestations associated with Dravet syndrome or the root cause of the disease, but there are types of gene therapy approaches that may offer hope. Learn more about gene regulation therapy and its potential role for treating Dravet syndrome.
Переглядів: 53

Відео

ASGCT 2023 Presentation Overview
Переглядів 245Рік тому
Encoded Therapeutics addresses common source of gene therapy toxicity while achieving precise brain expression in non-human primates Presented at the American Society of Gene and Cell Therapy 26th Annual Meeting View our press release here: encoded.com/press-releases/asgct2023/
AES 2022 ENVISION Presentation Overview
Переглядів 802 роки тому
At the AES 2022 Annual Meeting, Encoded is sharing findings from our 1-year follow-up in the ENVISION natural history study: ➡️ Seizure burden for people living with Dravet syndrome remains high despite multiple and newer antiseizure meds (ASMs) ➡️ Cognition is universally impacted by age 2 years, and incremental gains in language deviate substantially from neurotypical peers ➡️ Impairment to d...
ESGCT 2022 Presentation Overview
Переглядів 1322 роки тому
Optimized human regulatory sequences achieve targeted expression in brain and decreased off-target liver and dorsal root ganglion expression European Society of Gene and Cell Therapy 29th Congress Presentation Overview With Dr. Raghu Hosur, Director of Technology
Encoded Lab Tour
Переглядів 1,5 тис.2 роки тому
Join us on a virtual tour of the labs at Encoded's headquarters in South San Francisco. Hear from Co-founder and Chief Scientific Officer Stephanie Tagliatela. Talented members from our Tech, Biorepository, Histology, Translational and Analytical Development teams explain what goes on behind the scenes as we work to develop potential gene therapies.
ASGCT 2022 Presentation Preview
Переглядів 2502 роки тому
Encoded Therapeutics to Present Nonclinical Data Showing Targeted Brain Expression While De-Targeting the Liver With Genomic Medicine Platform at the American Society for Cell and Gene Therapy 25th Annual Meeting Click here for details: encoded.com/press-releases/encoded-therapeutics-to-present-nonclinical-data-showing-targeted-brain-expression-while-de-targeting-the-liver-with-genomic-medicine...
Overview of Systematic Literature Review of the Burden of Dravet Syndrome
Переглядів 1072 роки тому
This month, the journal Epilepsy & Behavior published a systematic literature review (SLR) of the burden of Dravet syndrome that summarized contemporary studies reporting the clinical, humanistic and economic burden of Dravet syndrome. The SLR also identified important gaps that remain despite the increasing number of published manuscripts in the last decade. Encoded Chief Medical Officer Dr. S...
Part 3: AAV-mediated Gene Therapy for Developmental and Epileptic Encephalopathies
Переглядів 1522 роки тому
Developmental and Epileptic Encephalopathies as Potential Candidates for Gene Therapy presented by Dr. Sarah Weckhuysen of the University of Antwerp, and member of the Dravet Syndrome Foundation Scientific Advisory Board. This recording is part three of a three-part educational webinar series intended for healthcare providers. This educational series is provided by the Dravet Syndrome Foundatio...
Part 2: AAV-mediated Gene Therapy for Developmental and Epileptic Encephalopathies
Переглядів 1452 роки тому
Translational and Clinical Considerations of AAV-mediated Gene Therapy presented by Dr. Michael W. Lawlor of the Medical College of Wisconsin. This recording is part two of a three-part educational webinar series intended for healthcare providers. This educational series is provided by the Dravet Syndrome Foundation in collaboration with Encoded Therapeutics. Several years ago, gene therapy sti...
Part 1: AAV-mediated Gene Therapy for Developmental and Epileptic Encephalopathies
Переглядів 2752 роки тому
Introduction to AAV-mediated Gene Therapy presented by Dr. Michael W. Lawlor of the Medical College of Wisconsin. This recording is part one of a three-part educational webinar series intended for healthcare providers. This educational series is provided by the Dravet Syndrome Foundation in collaboration with Encoded Therapeutics. Several years ago, gene therapy still seemed a distant possibili...
Encoded Holiday Greeting 2021
Переглядів 983 роки тому
Happy Holidays from the team at Encoded Therapeutics!
AES 2021 ENVISION Presentation Preview
Переглядів 713 роки тому
Encoded Therapeutics to Present Initial ENVISION Natural History Study Data of Children With SCN1A Dravet Syndrome at the American Epilepsy Society 2021 Annual Meeting Click here for details on Encoded's AES 2021 presentations: encoded.com/press-releases/aes-2021/
Encoded Celebrates Rare Disease Day 2021
Переглядів 733 роки тому
Encoded Celebrates Rare Disease Day 2021
For Health Care Professionals - Dravet Syndrome: Potential Role of Gene Regulation Therapy
Переглядів 2023 роки тому
For Health Care Professionals: Dravet syndrome is a severe, refractory developmental and epileptic encephalopathy characterized by frequent prolonged seizures, status epilepticus events, significant cognitive stagnation, sleep abnormalities, motor impairment, and profound behavioral difficulties. There are currently no approved therapies that address the full spectrum of manifestations associat...
Encoded CEO Named to SF Business Times’ 2021 Class of “40 Under 40”
Переглядів 473 роки тому
Congratulations to our CEO, Kartik Ramamoorthi, on being one of San Francisco Business Times’ “40 Under 40!” Thanks to everyone in this year’s class of top executives for making a difference in our local business community. bit.ly/2QQyfht #SFBT40Under40